New pill shows promise for tough blood cancers in early trial

NCT ID NCT04139434

First seen Jan 27, 2026 · Last updated Apr 29, 2026 · Updated 17 times

Summary

This early-phase study tested an experimental oral drug called LP-108, given alone or with another drug (azacitidine), in 32 adults with certain blood cancers (MDS, CMML, or AML) that had returned or stopped responding to prior therapy. The main goals were to find the safest dose and understand how the drug moves through the body. This is not a cure; it aims to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hospital San Pedro de Alcántara

    Cáceres, Cáceres, 10003, Spain

  • Institut Català d'oncologia - ICO Badalona

    Badalona, Barcelona, 08916, Spain

  • Instituto de Investigación Sanitaria La Fe

    Valencia, Valencia, CP 46026, Spain

  • MD Anderson Cancer Center

    Huston, Texas, 77030, United States

  • Ohio State Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • University of Cincinnati

    Cincinnati, Ohio, 45221, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

Conditions

Explore the condition pages connected to this study.